Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Withanone as an Emerging Anticancer Agent and Understanding Its Molecular Mechanisms: Experimental and Computational Evidence
Curr Cancer Drug Targets. 2024 Mar 14. doi: 10.2174/0115680096290673240223043650. Online ahead of print.ABSTRACTDespite decades of research and effort, treating cancer is still a challenging task. Current conventional treatments are still unsatisfactory to fully eliminate and prevent re-emergence or relapses, and targeted or personalised therapy, which are more effective in managing cancer, may be unattainable or inaccessible for some. In the past, research in natural products have yielded some of the most commonly used cancer treatment drugs known today. Hence it is possible more are awaiting to be discovered. Withanone, ...
Source: Current Cancer Drug Targets - March 18, 2024 Category: Cancer & Oncology Authors: Annatasha Stephen Bernadette Xin Jie Tune Yuan Seng Wu Kalaivani Batumalaie Mahendran Sekar Md Moklesur Rahman Sarker Vetriselvan Subramaniyan Neeraj Kumar Fuloria Shivkanya Fuloria Subash C B Gopinath Source Type: research

Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy
CONCLUSION: Our analysis preliminarily describes the complex function of CMPK2 in cancer progression and immune microenvironment highlighting its potential as a diagnostic and therapeutic target for immunotherapy.PMID:38486392 | DOI:10.2174/0115680096281451240306062101 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 15, 2024 Category: Cancer & Oncology Authors: Jingyuan Luo Qianyue Zhang Shutong Wang Luojie Zheng Jie Liu Yuchen Zhang Yingchen Wang Ranran Wang Zhigang Xiao Zheng Li Source Type: research

Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy
CONCLUSION: Our analysis preliminarily describes the complex function of CMPK2 in cancer progression and immune microenvironment highlighting its potential as a diagnostic and therapeutic target for immunotherapy.PMID:38486392 | DOI:10.2174/0115680096281451240306062101 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 15, 2024 Category: Cancer & Oncology Authors: Jingyuan Luo Qianyue Zhang Shutong Wang Luojie Zheng Jie Liu Yuchen Zhang Yingchen Wang Ranran Wang Zhigang Xiao Zheng Li Source Type: research

Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy
CONCLUSION: Our analysis preliminarily describes the complex function of CMPK2 in cancer progression and immune microenvironment highlighting its potential as a diagnostic and therapeutic target for immunotherapy.PMID:38486392 | DOI:10.2174/0115680096281451240306062101 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 15, 2024 Category: Cancer & Oncology Authors: Jingyuan Luo Qianyue Zhang Shutong Wang Luojie Zheng Jie Liu Yuchen Zhang Yingchen Wang Ranran Wang Zhigang Xiao Zheng Li Source Type: research

HAND2-AS1 Promotes Ferroptosis to Reverse Lenvatinib Resistance in Hepatocellular Carcinoma by TLR4/NOX2/DUOX2 Axis
CONCLUSION: These findings suggested that HAND2-AS1 may be a potential therapeutic target and an indicator of early recurrence for HCC.PMID:38465433 | DOI:10.2174/0115680096279597240219055135 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 11, 2024 Category: Cancer & Oncology Authors: Zheng Song Yu Zhang Wei Luo Chao Sun Caihong Lv Sihao Wang Quanwei He Ran Xu Zhaofang Bai Xiujuan Chang Yongping Yang Source Type: research

Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review
CONCLUSION: The condition of the patient remained stable until May 2023, indicating a progression-free survival of over 24 months. This case suggests that T-DXd may offer long-term clinical benefits in patients with HER2-amplified advanced gastric cancer with brain metastases.PMID:38465434 | DOI:10.2174/0115680096283210240209062301 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 11, 2024 Category: Cancer & Oncology Authors: Haibo Zhang Min Xu Source Type: research

HAND2-AS1 Promotes Ferroptosis to Reverse Lenvatinib Resistance in Hepatocellular Carcinoma by TLR4/NOX2/DUOX2 Axis
CONCLUSION: These findings suggested that HAND2-AS1 may be a potential therapeutic target and an indicator of early recurrence for HCC.PMID:38465433 | DOI:10.2174/0115680096279597240219055135 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 11, 2024 Category: Cancer & Oncology Authors: Zheng Song Yu Zhang Wei Luo Chao Sun Caihong Lv Sihao Wang Quanwei He Ran Xu Zhaofang Bai Xiujuan Chang Yongping Yang Source Type: research

Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review
CONCLUSION: The condition of the patient remained stable until May 2023, indicating a progression-free survival of over 24 months. This case suggests that T-DXd may offer long-term clinical benefits in patients with HER2-amplified advanced gastric cancer with brain metastases.PMID:38465434 | DOI:10.2174/0115680096283210240209062301 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 11, 2024 Category: Cancer & Oncology Authors: Haibo Zhang Min Xu Source Type: research

HAND2-AS1 Promotes Ferroptosis to Reverse Lenvatinib Resistance in Hepatocellular Carcinoma by TLR4/NOX2/DUOX2 Axis
CONCLUSION: These findings suggested that HAND2-AS1 may be a potential therapeutic target and an indicator of early recurrence for HCC.PMID:38465433 | DOI:10.2174/0115680096279597240219055135 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 11, 2024 Category: Cancer & Oncology Authors: Zheng Song Yu Zhang Wei Luo Chao Sun Caihong Lv Sihao Wang Quanwei He Ran Xu Zhaofang Bai Xiujuan Chang Yongping Yang Source Type: research